Patents Assigned to LEITERS, Inc.
  • READY-TO-USE BUPIVISONE PLUS LIQUID FORMULATION
    Publication number: 20220354870
    Abstract: The present disclosure provides a ready-to-use liquid formulation comprising bupivacaine hydrochloride, dexamethasone sodium phosphate and epinephrine (collectively referred to as Bupivisone Plus), and methods for preparing, packaging, storing and using the same.
    Type: Application
    Filed: April 14, 2022
    Publication date: November 10, 2022
    Applicant: LEITERS, Inc.
    Inventors: Dominic Ventura, Dona Wickramaratne, Chris Zuccarelli, Glenn HUTH, Mark THOMAS